Physician profile
Morgan B Bowen
NPI 1003410697
$3,959.43
in general payments reported to CMS, 2019-2025
20 companies · $877 in 2025
The $877 reported for 2025 was more than what 83% of Psychiatric/Mental Health, Adult (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $849 · 2022: $1,228 · 2023: $475 · 2024: $531 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,882.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $567.70 | 2021-2025 | Spravato |
| Alkermes, INC. | $493.77 | 2021-2025 | Aristada, Lybalvi |
| Abbvie INC. | $422.62 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $357.91 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $350.92 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $339.35 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $298.70 | 2021-2025 | Ingrezza |
| Corium, LLC | $247.99 | 2024-2025 | Azstarys |
| Lundbeck LLC | $187.90 | 2021-2025 | Rexulti |
| Jazz Pharmaceuticals INC. | $166.03 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $154.36 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $135.23 | 2021-2025 | Trintellix |
| Eisai INC. | $41.30 | 2021 | |
| Biogen, INC. | $40.98 | 2025 | Zurzuvae |
| Ironshore Pharmaceuticals INC. | $36.05 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $32.53 | 2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $31.96 | 2023-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $27.12 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $14.95 | 2021 | |
| Brainsway USA INC | $12.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Bowen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.